Metabolic

Retatrutide

Also known as LY3437943

Investigational triple agonist (GIP / GLP-1 / glucagon) in late-stage trials.

Overview

Retatrutide is an Eli Lilly–developed triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials reported ~24% mean weight reduction at 48 weeks at the highest dose.

Mechanism

GIP + GLP-1 (insulinotropic, satiety) plus glucagon (energy expenditure, lipolysis).

Research areas

Obesity
Type 2 diabetes
MASH

Related peptides

Semaglutide

Long-acting GLP-1 receptor agonist for glycemic control and weight management.

View

Tirzepatide

Dual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.

View

Cagrilintide

Long-acting amylin analog studied alongside semaglutide as CagriSema.

View